Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Sanofi, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Sanofi, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Sanofi, Medical Equipment, Deal Details 15
Asset Purchase 15
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 15
Sanofi Plans to Acquire Medical Device Assets 16
Venture Financing 17
True North Therapeutics Raises USD45 Million in Series D Financing 17
Portal Instruments Raises USD25 Million in Series B Financing 18
Portal Instruments Raises USD11 Million in Series A Venture Financing 19
Private Equity 20
Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 20
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 22
Partnerships 23
Ablynx Exercises Option for Licensing Agreement with Vectura 23
Sensile Medical, Sanofi and Verily Enter into Co-Development Agreement 24
Adaptive Biotechnologies Enters into Agreement with Sanofi 25
Berg Enters into Research Agreement with Sanofi 26
Bioverativ and Invicro Enter into Agreement 27
Sanofi and Voluntis Enter into Agreement 28
R-Health Enters into Agreement with Bioverativ 29
Sanofi and Verily Life Sciences Form Joint Venture 30
Global Genomics Enters into Research Agreement with Sanofi 31
Google Life Sciences Enters into Agreement with Sanofi 32
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33
Sanofi Enters into Co-Development Agreement with Medtronic 34
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 35
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 36
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 37
Merger 38
Sanofi Japan and Genzyme Japan Merge 38
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 39
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 40
Equity Offering 41
JHL Biotech Raises USD80 Million in Private Placement of Shares 41
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 42
Ablynx Raises USD57 Million in Private Placement of Shares 43
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Debt Offering 45
Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 45
Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 46
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 47
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 48
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 49
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 50
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 51
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 52
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 53
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 54
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 55
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 56
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 57
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 58
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 59
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 60
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 62
Acquisition 63
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 63
Bioverativ Therapeutics Acquires True North Therapeutics 65
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 66
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 67
L’Oreal Plans To Sell Its Stake In Sanofi 68
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 69
Sanofi Completes Acquisition Of Pluromed 71
Sanofi – Key Competitors 72
Sanofi – Key Employees 73
Sanofi – Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Joint Venture 89
Recent Developments 90
Strategy And Business Planning 90
Sep 13, 2018: Sanofi to refocus two global business units 90
Financial Announcements 91
Mar 28, 2018: Sanofi: Pre – quarterly R esults C ommunication 91
Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 93
Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 100
Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 106
Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 108
Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 114
Corporate Communications 122
Jul 26, 2018: Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st 122
Jun 19, 2018: Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer 123
May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 124
Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 125
Mar 06, 2018: Sanofi’s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 126
Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 127
Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 128
Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 129
Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 131
Mar 02, 2017: Sanofi’s Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 132
Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 133
Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 134
Legal and Regulatory 135
Dec 31, 2017: Sanofi reaches civil settlement with US SEC 135
Other Significant Developments 136
Jun 13, 2018: DTxDM – the Home of Validated Digital Healthcare, Announces Its Founding Partners at the Launch of the New Hub for Everyone Working in Digital Therapeutics and Digital Medicine 136
May 28, 2018: Beactica Signs Three-Year Extension Agreement With Sanofi 137
Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER 138
Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 145
Nov 16, 2017: Blue Cross and Blue Shield Companies Partner with Onduo on Three State Pilot Programs to Address Diabetes 147
Sep 25, 2017: Innovation Health Announces Pilot Program with Sanofi to Improve Care Delivery for People Living with Type 2 Diabetes 148
Appendix 149
Methodology 149
About GlobalData 149
Contact Us 149
Disclaimer 149
Sanofi, Medical Equipment, Key Facts, 2017 2
Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Sanofi, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Sanofi, Deals By Market, 2012 to YTD 2018 11
Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 15
Sanofi Plans to Acquire Medical Device Assets 16
True North Therapeutics Raises USD45 Million in Series D Financing 17
Portal Instruments Raises USD25 Million in Series B Financing 18
Portal Instruments Raises USD11 Million in Series A Venture Financing 19
Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 20
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 22
Ablynx Exercises Option for Licensing Agreement with Vectura 23
Sensile Medical, Sanofi and Verily Enter into Co-Development Agreement 24
Adaptive Biotechnologies Enters into Agreement with Sanofi 25
Berg Enters into Research Agreement with Sanofi 26
Bioverativ and Invicro Enter into Agreement 27
Sanofi and Voluntis Enter into Agreement 28
R-Health Enters into Agreement with Bioverativ 29
Sanofi and Verily Life Sciences Form Joint Venture 30
Global Genomics Enters into Research Agreement with Sanofi 31
Google Life Sciences Enters into Agreement with Sanofi 32
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33
Sanofi Enters into Co-Development Agreement with Medtronic 34
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 35
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 36
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 37
Sanofi Japan and Genzyme Japan Merge 38
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 39
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 40
JHL Biotech Raises USD80 Million in Private Placement of Shares 41
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 42
Ablynx Raises USD57 Million in Private Placement of Shares 43
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 45
Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 46
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 47
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 48
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 49
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 50
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 51
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 52
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 53
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 54
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 55
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 56
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 57
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 58
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 59
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 60
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 62
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 63
Bioverativ Therapeutics Acquires True North Therapeutics 65
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 66
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 67
L'Oreal Plans To Sell Its Stake In Sanofi 68
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 69
Sanofi Completes Acquisition Of Pluromed 71
Sanofi, Key Competitors 72
Sanofi, Key Employees 73
Sanofi, Subsidiaries 75
Sanofi, Joint Venture 89
List of Figures
Sanofi, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Sanofi, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Sanofi, Medical Equipment, Deals by Market, 2012 to YTD 2018 11
